☆ 4.3 Review

Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2015)

期刊

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE

卷 9, 期 5, 页码 242-250

出版社

SAGE PUBLICATIONS LTD

DOI: 10.1177/1753465815587820

关键词

AZD9291; CO-1686; epidermal growth factor receptor activating mutations; HM61713; non-small cell lung cancer; tyrosine kinase inhibitors; T790M mutation

类别

Respiratory System

向作者/读者索取更多资源

Protocol

Reagent

摘要

The discovery of epidermal growth factor receptor activating mutations (EGFR Mut+) has determined a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. However, despite these impressive results, most patients with NSCLC EGFR Mut+ develop acquired resistance to TKIs. This review will discuss both the mechanisms of resistance to TKIs and the therapeutic strategies to overcome resistance, including emerging data on third-generation TKIs.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report

Zi-Wei Chen, Gigin Lin, Hsuan-Jen Shih, Chiao-En Wu

Summary: This article reports a case of a patient with non-small cell lung cancer with EGFR gene mutations who responded well to brigatinib monotherapy after intolerable adverse events from afatinib and osimertinib treatments. The patient had EGFR del19/T790M/cis-C797S mutations.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Chemistry, Medicinal

Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-GenerationEpidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations

Hao Chen, Mengzhen Lai, Tao Zhang, Yuqing Chen, Linjiang Tong, Sujie Zhu, Yang Zhou, Xiaomei Ren, Jian Ding, Hua Xie, Xiaoyun Lu, Ke Ding

Summary: This study reports the development of a novel EGFRT790M/C797S inhibitor that effectively inhibits the proliferation of EGFR-mutated NSCLC cells, suggesting a potential clinical application.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Oncology

MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance

Robin Guo, Michael Offin, A. Rose Brannon, Jason Chang, Andrew Chow, Lukas Delasos, Jeffrey Girshman, Olivia Wilkins, Caroline G. McCarthy, Alex Makhnin, Christina Falcon, Kerry Scott, Yuan Tian, Fabiola Cecchi, Todd Hembrough, Deepu Alex, Ronglai Shen, Ryma Benayed, Bob T. Li, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Natasha Rekhtman, Paul Paik, Ahmet Zehir, Alexander Drilon

Summary: In MET exon 14-altered lung cancers treated with a MET TKI, the genomic mechanisms of primary resistance remain unknown, while MET expression is correlated with treatment benefit.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Aumolertinib: A Review in Non-Small Cell Lung Cancer

Matt Shirley, Susan J. Keam

Summary: Aumolertinib, a new-generation EGFR-TKI, shows promising efficacy and tolerability for both first-line and second-line treatment of advanced EGFR mutation-positive NSCLC, according to clinical trials conducted in China.

DRUGS (2022)

添加到收藏夹

Article Chemistry, Medicinal

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance

M. Raymond Finlay, Peter Barton, Sue Bickerton, Michal Bista, Nicola Colclough, Darren A. E. Cross, Laura Evans, Nicolas Floc'h, Clare Gregson, Carine M. Guerot, David Hargreaves, Xiaoming Kang, Eva M. Lenz, Xu Li, Yi Liu, Olivier Lorthioir, Matthew J. Martin, Darren McKerrecher, Claire McWhirter, Daniel O'Neill, Jonathan P. Orme, Arash Mosallanejad, Amar Rahi, Paul D. Smith, Verity Talbot, Richard A. Ward, Gail Wrigley, Marta Wylot, Lin Xue, Tieguang Yao, Yang Ye, Xiliang Zhao

Summary: The research focused on the medicinal chemistry optimization of a biochemically potent but modestly cell-active, reversible EGFR inhibitor with sub-optimal physicochemical properties, leading to the discovery of compound 12 with improved cell potency, oral exposure, and in vivo activity in clinically relevant EGFR-mutant-driven disease models.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Oncology

Osimertinib plus Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON

Ryan J. Hartmaier, Aleksandra A. Markovets, Myung Ju Ahn, Lecia Sequist, Ji-Youn Han, Byoung Chul Cho, Helena A. Yu, Sang-We Kim, James Chih-Hsin Yang, Jong-Seok Lee, Wu-Chou Su, Dariusz M. Kowalski, Sergey Orlov, Song Ren, Paul Frewer, Xiaoling Ou, Darren A. E. Cross, Nisha Kurian, Mireille Cantarini, Pasi A. Jaenne

Summary: Combining MET inhibitor and EGFR tyrosine kinase inhibitor can overcome acquired osimertinib resistance mediated by MET. In this study, savolitinib and osimertinib combination therapy showed promising results in advanced non-small cell lung cancer patients with MET amplification and EGFR mutation who had progressed on prior EGFR-TKI treatment. The combination therapy demonstrated acceptable safety profile and improved antitumor activity.

CANCER DISCOVERY (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

Tyler S. Beyett, Ciric To, David E. Heppner, Jaimin K. Rana, Anna M. Schmoker, Jaebong Jang, Dries J. H. De Clercq, Gabriel Gomez, David A. Scott, Nathanael S. Gray, Pasi A. Janne, Michael J. Eck

Summary: This study investigates the molecular mechanisms and structural basis of drug resistance in lung cancer and the combination of allosteric and ATP-competitive inhibitors to overcome resistance. The findings highlight the importance of the P-loop in the synergy between allosteric inhibitors and EGFR variants.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Kamrine E. Poels, Adam J. Schoenfeld, Alex Makhnin, Yosef Tobi, Yuli Wang, Heidie Frisco-Cabanos, Shaon Chakrabarti, Manli Shi, Chelsi Napoli, Thomas O. McDonald, Weiwei Tan, Aaron Hata, Scott L. Weinrich, Helena A. Yu, Franziska Michor

Summary: In this study, a computational model was used to identify an optimal dosing schedule for combination therapy of osimertinib and dacomitinib, which was confirmed tolerable and effective in an ongoing phase I clinical trial.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Meredith S. Eno, Jason D. Brubaker, John E. Campbell, Chris De Savi, Timothy J. Guzi, Brett D. Williams, Douglas Wilson, Kevin Wilson, Natasja Brooijmans, Joseph Kim, Aysegul Ozen, Emanuele Perola, John Hsieh, Victoria Brown, Kristina Fetalvero, Andrew Garner, Zhuo Zhang, Faith Stevison, Rich Woessner, Jatinder Singh, Yoav Timsit, Caitlin Kinkema, Clare Medendorp, Christopher Lee, Faris Albayya, Alena Zalutskaya, Stefanie Schalm, Thomas A. Dineen

Summary: While EGFR tyrosine kinase inhibitors have revolutionized the treatment of NSCLC, the development of resistance mutations remains a challenge. This study introduces a novel reversible inhibitor, BLU-945, that shows promising activity against different resistance mutations. Clinical trials are currently underway to evaluate its efficacy and safety.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Oncology

Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)

James Chih-Hsin Yang, Yuichiro Ohe, Chao -Hua Chiu, Xiaoling Ou, Mireille Cantarini, Pasi A. Janne, Ryan J. Hartmaier, Myung Ju Ahn

Summary: The combination of osimertinib and selumetinib showed promising antitumor activity and tolerability in patients with MET-negative, EGFRm advanced NSCLC who had progressed on previous EGFR-TKI treatment.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Chemistry, Medicinal

A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma

Muammar Fawwaz, Kenji Mishiro, Ryuichi Nishii, Akira Makino, Yasushi Kiyono, Kazuhiro Shiba, Seigo Kinuya, Kazuma Ogawa

Summary: The study aimed to develop a PET imaging probe for detecting EGFR L858R/T790M mutations, and [Br-77]BrCO1686 showed high cytotoxicity and significant accumulation in tumor cells, indicating potential as a molecular probe for targeted imaging.

PHARMACEUTICALS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer

Geunho Choi, Daegeun Kim, Junehwan Oh

Summary: This study utilized artificial intelligence to discover potential drugs that can overcome acquired resistance in lung cancer patients, reducing the limitations of the current drug discovery process.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma

Hyoung-oh Jeong, Hayoon Lee, Hyemin Kim, Jinho Jang, Seunghoon Kim, Taejoo Hwang, David Whee-Young Choi, Hong Sook Kim, Naeun Lee, Yoo Mi Lee, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Semin Lee, Se-Hoon Lee

Summary: The study found that specific cell types such as lung epithelial precursor cells and transitional effector T cells, as well as an immunosuppressive microenvironment, were enriched in the MPE of EGFR TKI-resistant patients, potentially associated with their response to TKI therapy.

ISCIENCE (2022)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Ethacrynic Acid Enhances the Antitumor Effects of Afatinib in EGFR/T790M-Mutated NSCLC by Inhibiting WNT/Beta-Catenin Pathway Activation

Xuehui Zhang, Chaoyuan Huang, Biyu Cui, Yebin Pang, Rong Liang, Xiaoling Luo

Summary: The combination of afatinib with ethacrynic acid showed strong synergistic antitumor effects in EGFR L858R/T790M-mutated NSCLC cells by inhibiting the activation of the WNT/beta-catenin pathway and suppressing the secretion of anti-inflammatory factors, providing a new therapeutic approach and potential for developing new drugs or optimizing afatinib dosage in clinical use for future antitumor therapy.

DISEASE MARKERS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma

Milena Casula, Marina Pisano, Panagiotis Paliogiannis, Maria Colombino, Maria Cristina Sini, Angelo Zinellu, Davide Santeufemia, Antonella Manca, Stefania Casula, Silvia Tore, Renato Lobrano, Antonio Cossu, Giuseppe Palmieri

Summary: Oncogenic mutations in the EGFR gene are targets of tyrosine kinase inhibitors in lung adenocarcinoma patients. Liquid biopsy of ctDNA is increasingly used to detect EGFR mutations. This study compared three different techniques and found that real-time PCR-based methods showed equivalent detection ability to the NGS assay for circulating EGFR mutations, but the NGS assay had a poor ability to detect T790M.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

Somatostatin Analog Therapy in Small Cell Lung Cancer

Alfredo Tartarone, Rosa Lerose, Michele Aieta

SEMINARS IN NUCLEAR MEDICINE (2016)

添加到收藏夹

Article Oncology

Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study

Elena Verzoni, Ugo De Giorgi, Lisa Derosa, Orazio Caffo, Francesco Boccardo, Gaetano Facchini, Luca Porcu, Fabio De Vincenzo, Alberto Zaniboni, Vincenzo Emanuele Chiuri, Lucia Fratino, Daniele Santini, Vincenzo Adamo, Rocco De Vivo, Angelo Dinota, Caterina Messina, Riccardo Ricotta, Claudia Caserta, Claudio Scavelli, Marina Susi, Alfredo Tartarone, Giuseppe Surace, Alessandra Mosca, Michele Bruno, Sandro Barni, Paolo Grassi, Giuseppe Procopio

ONCOTARGET (2016)

添加到收藏夹

Article Oncology

Possible applications of circulating tumor cells in patients with non small cell lung cancer

Alfredo Tartarone, Elisabetta Rossi, Rosa Lerose, Giuseppina Mambella, Giuseppe Calderone, Rita Zamarchi, Michele Aieta

LUNG CANCER (2017)

添加到收藏夹

Review Oncology

Progress and challenges in the treatment of small cell lung cancer

Alfredo Tartarone, Pasqualina Giordano, Rosa Lerose, Maria Grazia Rodriquenz, Raffaele Conca, Michele Aieta

MEDICAL ONCOLOGY (2017)

添加到收藏夹

Editorial Material Respiratory System

The era of a liquid biopsy may be on the horizon in non-small cell lung cancer Preface

Alfredo Tartarone

JOURNAL OF THORACIC DISEASE (2017)

添加到收藏夹

Review Respiratory System

Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer

Alfredo Tartarone, Rosa Lerose, Maria Grazia Rodriquenz, Giuseppina Mambella, Giuseppe Calderoni, Giovanni Bozza, Michele Aieta

JOURNAL OF THORACIC DISEASE (2017)

添加到收藏夹

Article Respiratory System

Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared

Mariangela Manicone, Maria Chiara Scaini, Maria Grazia Rodriquenz, Antonella Facchinetti, Alfredo Tartarone, Michele Aieta, Rita Zamarchi, Elisabetta Rossi

JOURNAL OF THORACIC DISEASE (2017)

添加到收藏夹

Review Oncology

Is there a role for immunotherapy in malignant pleural mesothelioma?

Alfredo Tartarone, Rosa Lerose, Michele Aieta

MEDICAL ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis

Alfredo Tartarone, Giandomenico Roviello, Rosa Lerose, Raheleh Roudi, Michele Aieta, Pietro Zoppoli

FUTURE ONCOLOGY (2019)

添加到收藏夹

Article Nursing

Oral anticancer therapy project: Clinical utility of a specific home care nursing programme on behalf of Italian Association of Medical Oncology (AIOM)

Massimo Cirillo, Luciano Carlucci, Lorenzo Legramandi, Editta Baldini, Cosimo Sacco, Vittorina Zagonel, Silvana Leo, Francesca Di Fabio, Giuseppe Tonini, Maria Luisa Meacci, Alfredo Tartarone, Daniele Farci, Giampaolo Tortora, Marta Zaninelli, Vanna Maria Valori, Saverio Cinieri, Francesco Carrozza, Enrico Barbato, Valentina Fabbroni, Elisabetta Cretella, Teresa Gamucci, Gianluigi Lunardi, Sonia Zamboni, Giovanni Micallo, Stefano Cascinu, Carmine Pinto, Stefania Gori

JOURNAL OF CLINICAL NURSING (2020)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.